|1.||Sadeghian, Hamid: 4 articles (01/2015 - 04/2008)|
|2.||Movsesian, Matthew: 3 articles (05/2015 - 01/2015)|
|3.||Abe, Jun-ichi: 3 articles (11/2013 - 05/2005)|
|4.||Yan, Chen: 3 articles (11/2013 - 05/2005)|
|5.||Yoshida, Hideo: 3 articles (03/2012 - 03/2011)|
|6.||Parsaee, Heydar: 3 articles (01/2010 - 04/2008)|
|7.||Seyedi, Seyed Mohammad: 3 articles (01/2010 - 04/2008)|
|8.||Shafiee-Nick, Reza: 2 articles (01/2015 - 04/2008)|
|9.||Blaxall, Burns C: 2 articles (11/2013 - 05/2005)|
|10.||Miller, Clint L: 2 articles (11/2013 - 03/2007)|
01/01/2015 - "Therefore, in comparison with the clinically available selective PDE3 inhibitors, MC2 has lowest metabolic side effects and might be a good candidate for treatment of congestive heart failure."
01/01/2011 - "In failing hearts, these responses are attenuated solely by PDE3 and thus even selective PDE3 inhibitors may provide a profound enhancement of β-adrenoceptor-mediated responses in heart failure."
01/15/2010 - "Selective PDE3 (phosphodiesterase 3) inhibitors improve cardiac contractility and may be used in congestive heart failure. "
08/01/2009 - "Selective PDE3 inhibitors improve cardiac contractility and may be used in congestive heart failure. "
04/01/2008 - "Selective phosphodiesterase (PDE3) inhibitors improve cardiac contractility and may use in congestive heart failure. "
01/01/2015 - "Clinical experience with phosphodiesterase 3 inhibitors (PDE3i) in pediatric patients with IDC, however, demonstrates improved heart failure symptoms without the increased incidence of sudden death seen in adults treated with PDE3i. "
11/01/2013 - "PDE3 inhibitors are used for acute treatment of congestive heart failure, but are associated with increased incidence of arrhythmias and sudden death with long-term use. "
07/01/2012 - "The basic pharmacology of PDE inhibitors is presented and the use of PDE-3 inhibitors for the treatment of heart failure causing an increase in sudden death is also reviewed. "
12/01/2004 - "PDE3 inhibitors may be clinically useful in the treatment of delayed cerebral vasospasm after subarachnoid hemorrhage. "
04/05/2004 - "This suggests that phosphodiesterase 3 inhibitors are still effective under conditions with possible dysfunctional nitric oxide-cGMP pathway, such as in ischemic stroke or cerebral vasospasm."
|4.||Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
01/01/2013 - "Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line."
12/28/2005 - "The aims of this study were to examine the vasorelaxant effects of three phosphodiesterase 3 (PDE3) inhibitors, olprinone, milrinone and amrinone, on isolated gastroepiploic arterial preparations in comparison with a calcium channel blocker diltiazem, and to confirm the mRNA expression of PDE3A isoenzyme using reverse transcription-polymerase chain reaction (RT-PCR) in the human gastroepiploic artery isolated from stomach removed in cancer surgery. "
|1.||Type 3 Cyclic Nucleotide Phosphodiesterases
|4.||Calcium Channels (Calcium Channel)
|5.||Messenger RNA (mRNA)
|9.||Phosphodiesterase 5 Inhibitors
|2.||Angioplasty (Angioplasty, Transluminal)
|3.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)